ALBAWABA - The U.S. Food and Drug Administration (FDA) has approved new Alzheimer's treatment from Eli Lilly for adults with early symptomatic Alzheimer's disease, brand named Kisunla, following multiple delays and regulatory hurdles. According to a statement by Eli Lilly, Kisunla “demonstrated very meaningful results for people with early symptomatic Alzheimer's disease” including individuals with verified amyloid pathology who have moderate cognitive impairment (MCI) or the mild dementia stage of ...